Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2015—NeoGenomics has reached an agreement to acquire Clarient and its wholly owned subsidiary Clarient Diagnostic Services. Clarient, a unit of GE Healthcare’s Life Sciences business, is based in Houston and in Aliso Viejo, Calif., and has approximately 415 employees. Clarient had 2014 revenue of $127 million.
December 2015—Inova Diagnostics announced the FDA clearance of Quanta Flash CCP3, an assay that aids in the diagnosis of rheumatoid arthritis. The fully automated chemiluminescent assay, which has demonstrated excellent clinical performance in large cohorts of RA and disease control patients, uses a third-generation cyclic citrullinated peptide technology from Inova Diagnostics.
December 2015—Dako announced FDA approval of a test that can identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells and provide information on the survival benefit with Opdivo (nivolumab) for patients with nonsquamous NSCLC.
December 2015—The Clinical and Laboratory Standards Institute published a new document titled “Laboratory Personnel Management (QMS16-Ed1).” This guideline describes the process for meeting the regulatory and accreditation requirements of personnel management in the laboratory environment.
December 2015—Luminex and Bio-Techne have signed a new distribution and supply agreement through 2020.
December 2015—Thermo Scientific’s DRI Hydrocodone Assay received FDA 510(k) clearance; it also has the requisite sensitivities to meet the newly proposed Substance Abuse and Mental Health Services Administration guidelines (using a 300 ng/mL cutoff). SAMHSA oversees the testing of federally regulated employees, and many organizations follow the guidelines set forth by this agency.
December 2015—Irvine Scientific released BalanCD Transfectory CHO, a cell culture medium for rapid, scalable production of recombinant proteins through transient transfection in CHO cells. The medium is chemically defined and animal component free and is designed to support sustained, high growth with increased transfection efficiency that can yield gram-scale protein expression.
December 2015—Rheonix raised $28.6 million to further expand the company’s commercialization efforts for its molecular testing platforms, the Encompass MDx and Encompass Optimum.
December 2015—Oxford Gene Technology has entered into a deal with Baylor Miraca Genetics Laboratories, licensing the use of OGT’s proprietary single nucleotide polymorphism array probe technology.
December 2015—Diagnostica Stago launched its next-generation ecarin-based chromogenic assay for dabigatran, STA-ECA II. Fully automated with barcoded loading on Stago’s high throughput analyzers, STA-ECA II enables laboratories to measure dabigatran (Pradaxa) in plasma samples and is insensitive to lupus anticoagulants and heparin along with coagulation factor and fibrinogen levels.
